-$0.40 EPS Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
Equities analysts expect Proteon Therapeutics, Inc. (NASDAQ:PRTO) to post earnings of ($0.40) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Proteon Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.52). Proteon Therapeutics posted earnings per share of ($0.43) in the same quarter last year, which would indicate a positive year over year growth rate of 7%. The firm is scheduled to announce its next quarterly earnings report on Monday, November 6th.
On average, analysts expect that Proteon Therapeutics will report full-year earnings of ($1.54) per share for the current financial year, with EPS estimates ranging from ($1.72) to ($1.42). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.64) per share, with EPS estimates ranging from ($1.81) to ($1.35). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Proteon Therapeutics.
Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.11.
A number of analysts recently issued reports on the company. HC Wainwright set a $2.00 price objective on Proteon Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. reissued a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Zacks Investment Research downgraded Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.25.
Proteon Therapeutics (NASDAQ:PRTO) opened at $2.00 on Monday.
A hedge fund recently bought a new stake in Proteon Therapeutics stock. RA Capital Management LLC acquired a new position in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up approximately 0.2% of RA Capital Management LLC’s holdings, making the stock its 22nd biggest position. RA Capital Management LLC owned approximately 7.59% of Proteon Therapeutics at the end of the most recent reporting period. 47.07% of the stock is owned by institutional investors.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.